DrugPatentWatch Database Preview
NURTEC ODT Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Nurtec Odt, and what generic alternatives are available?
Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has eighty patent family members in thirty-two countries.
The generic ingredient in NURTEC ODT is rimegepant sulfate. Additional details are available on the rimegepant sulfate profile page.
US ANDA Litigation and Generic Entry Outlook for Nurtec Odt
Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NURTEC ODT
| International Patents: | 80 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | NURTEC ODT at DailyMed |
Generic Entry Opportunity Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for NURTEC ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Biohaven Pharm | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NURTEC ODT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2820016 | Start Trial |
| Colombia | 6460732 | Start Trial |
| Eurasian Patent Organization | 201270561 | Start Trial |
| Australia | 2013226361 | Start Trial |
| Poland | 2820016 | Start Trial |
| Mexico | 2012004182 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
